Beau Bosko Toskich: MERITS-LT Trial Shows Comparable Survival for HCC Patients Outside UNOS Criteria
Beau Bosko Toskich, Professor of Radiology and Director of Interventional Oncology at Mayo Clinic Florida, posted on X:
“MERITS-LT: Downstaging hepatocellular carcinoma patients outside of UNOS-DS criteria (aka “all comers” or AC) results in similar post-transplant survival to those within criteria (3-year 91% vs 81%, P = .67).
What is your MDT using most commonly to downstage patients with HCC?
91.7% of respondents reported that their multidisciplinary team (MDT) most commonly uses TARE (Transarterial Radioembolization). TACE (Transarterial Chemoembolization) was chosen by 8.3%, while EBRT (External Beam Radiotherapy) and Systemic Therapy received 0% of the votes.”
The MERITS-LT study demonstrates that patients with hepatocellular carcinoma (HCC) who are downstaged outside the standard UNOS-DS criteria can achieve post-transplant survival comparable to those within the criteria, with a reported 3-year survival of 91% versus 81% respectively (P = .67). The majority of multidisciplinary teams (MDTs) reported using transarterial radioembolization (TARE) for downstaging, with limited use of TACE and no reported use of EBRT or systemic therapy.
Authors: Brahma Natarajan, Parissa Tabrizian, Maarouf Hoteit, Catherine Frenette, Neehar Parikh, Tara Ghaziani, Renu Dhanasekaran, Jennifer Guy, Amy Shui, Sander Florman, Francis Y. Yao, Neil Mehta
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023